Zetina M E, González-Noriega A
Rev Invest Clin. 1989 Oct-Dec;41(4):319-26.
Results obtained by the Lysosome Storage Disease Diagnostic Program are described as well as the criteria used for the selection of patients to be studied. This program was started in 1983 and is sponsored by the National Reference Center for the Detection and Diagnosis of Inborn Errors of Metabolism in Mexico City. Laboratory tests include chemical determinations of urinary glycosaminoglycans and enzymatic assays of 15 lysosomal enzymes that allow the identification of 25 of the 35 lysosomal storage diseases known. A total of 259 patients with clinical phenotypes suggesting a lysosomal storage disease, and 47 individuals at risk for the carrier state were studied. The disease diagnosed were 35 patients with mucopolysaccharidoses, 27 with sphingolipidoses, 5 with mucolipidoses and 7 with glycogenoses; the most common lysosomal storage disease was Gaucher followed in decreasing frequency by Morquio, Hunter and glycogenoses Ia. The carrier state was confirmed in 29 of close relatives, one of them confirmed prenatally.
本文描述了溶酶体贮积病诊断项目所获得的结果,以及用于选择研究患者的标准。该项目始于1983年,由墨西哥城国家先天性代谢缺陷检测与诊断参考中心赞助。实验室检测包括尿糖胺聚糖的化学测定和15种溶酶体酶的酶活性测定,这些检测能够识别已知的35种溶酶体贮积病中的25种。总共对259例具有溶酶体贮积病临床表型的患者和47例有携带者状态风险的个体进行了研究。确诊的疾病包括35例黏多糖贮积症患者、27例鞘脂贮积症患者、5例黏脂贮积症患者和7例糖原贮积症患者;最常见的溶酶体贮积病是戈谢病,其次是莫尔基奥氏病、亨特氏病和糖原贮积症Ia,发病率依次递减。在29名近亲中确认了携带者状态,其中1例是产前确诊的。